Trove
Sign In Sign Up

Pearl Therapeutics

Organization
Mentions
6
Relationships
1
Events
0
Documents
3
Search

Relationship Network

Loading... nodes
Interactive Network: Click nodes or edges to highlight connections and view details with action buttons. Drag nodes to reposition. Node size indicates connection count. Line color shows relationship strength: red (8-10), orange (6-7), yellow (4-5), gray (weak). Use legend and help buttons in the graph for more guidance.
1 total relationships
Connected Entity Relationship Type
Strength (mentions)
Documents Actions
organization NLV-III
Financial
5
1
View
No events found for this entity.

HOUSE_OVERSIGHT_024045.jpg

This document is a confidential investment report page (marked House Oversight) detailing the track record of New Leaf Ventures (NLV) in the biopharmaceutical sector. It highlights their investment strategy, networking capabilities, and specific performance metrics (multiples on invested capital) for various portfolio companies across funds NLV-I, NLV-II, and Sprout Funds. The text lists specific exits and IPOs occurring between 2011 and 2013.

Investment report / confidential memorandum (house oversight evidence)
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_024043.jpg

This document is page 32 of a confidential investment memorandum (Control Number 257) produced for the House Oversight Committee. It outlines the investment strategy for 'NLV-III' (New Leaf Ventures III), focusing on biopharmaceutical companies with novel products or platforms. The text highlights past successes of the fund managers, listing exit multiples for companies such as Array BioPharma, Pearl Therapeutics, and Epizyme.

Investment memorandum / prospectus (page 32)
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_024024.jpg

This document (page 13, Control Number 257) contains professional biographies for James Niedel and Liam Ratcliffe, executives at New Leaf Venture Partners. It details their educational backgrounds, board memberships, and extensive history in the pharmaceutical industry (GSK and Pfizer respectively), including specific successful drug developments and corporate acquisitions. The document is marked confidential and bears a House Oversight file stamp.

Corporate profile / investment team bio / house oversight document
2025-11-19
Analysis Source
Total Received
$0.00
0 transactions
Total Paid
$0.00
0 transactions
Net Flow
$0.00
0 total transactions
No financial transactions found for this entity. Entity linking may need to be improved.
As Sender
0
As Recipient
0
Total
0
No communications found for this entity. Entity linking may need to be improved.

Discussion 0

Sign in to join the discussion

No comments yet

Be the first to share your thoughts on this epstein entity

Back to Search